The Business Times
business-time-50

AstraZeneca spins off autoimmune drugs into new biotech company

Published Wed, Feb 28, 2018 · 09:50 PM

London

ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.

The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer.

AstraZeneca

TRENDING NOW

As demand for US bonds falls and yields rise, capital is typically drawn into the greenback, causing capital outflows from emerging market currencies.

Why US$100 oil, 5% US yields affect Singdollar, ringgit differently vs other Asean currencies

The need for multidisciplinary talent is becoming more pressing, with artificial intelligence now more widely used in the financial services industry.

Singapore fintechs struggle to find finance and tech talent

Asian investors continue to allocate capital to global markets, while maintaining significant exposure to US assets. 

Despite the de-dollarisation debate, demand for dollar liquidity in Asia is growing

Agmo CEO Tan Aik Keong’s unconventional rule is to “say yes first, then figure out how”.

Why Tan Aik Keong of digital solutions specialist Agmo wants to make himself less indispensable

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More